Healthcare Quality and Strategy Directorate Pharmacy and Medicines Division

T: 0131-244 2528 E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

- 1. Directors of Pharmacy
- 2. Chief Pharmacists NHS Boards
- 3. Hospital Pharmacy Managers
- 4. Medical Directors NHS Boards
- 5. Chief Executives NHS Boards

10 August 2016

Dear Healthcare Professional,

DRUG ALERT CLASS 2 no 10 2016 - Action within 48 hours

Please see the attached drug alert for onward transmission as below. Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

Please could Medical Directors forward this alert to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY Pharmacy and Medicines Division











DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours Pharmacy Level Recall

Date: 10 August 2016

EL (16)A/10

Our Ref: MDR 23-08/16

PL 10949/0275

Dear Healthcare Professional,

Glaxo Wellcome UK Limited

Respontin Nebules 250micrograms/1ml Respontin Nebules 500micrograms/2ml (Ipratropium Bromide)

Batch Number	Expiry Date	Pack Size	First Distributed
B76315BA	28.02.2017	20 x 1ml	30 Mar 2015
B85515J	31.10.2017	20 x 1ml	27 Jan 2016
B76315BA	28.02.2017	4 x 5 x 2ml	29 May 2015
B85515J	31.10.2017	4 x 5 x 2ml	18 Dec 2015

GlaxoSmithKline on behalf of the licence holder, Glaxo Wellcome UK Limited, is recalling the above batches because out of specification results for impurities were obtained during routine stability testing. No complaints or adverse reactions relating to this issue have been received by the company to date.

Remaining stocks of these batches should be quarantined and returned to the original supplier for credit. Please note, these products are being discontinued so no alternative batches are available however we understand that alternative versions of both presentations are available from a number of suppliers.

For returns and credit enquiries, please contact your local branch of AAH or Alliance Healthcare.

For medical information enquiries, please contact GlaxoSmithKline UK Medical Information Department on 0800 221 441 and choose Option 2

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. NHS Regional teams: please cascade to relevant clinics, general practitioners and community pharmacies.

Yours faithfully

Alison Bunce Pharmaceutical Assessor Defective Medicines Report Centre 151 Buckingham Palace Road London SW1W 9SZ Telephone +44 (0)20 3080 657